Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Controlled release agent of containing fluorouracil and synergist

A technology of synergist and uracil, which is applied in the field of anti-cancer sustained-release agents and its preparation, can solve the problems of poor curative effect, difficult operation, and many complications, and achieve the goals of reducing toxicity, facilitating drug injection, and reducing complications Effect

Inactive Publication Date: 2007-05-09
SHANDONG LANJIN PHARMA +1
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, solid sustained-release implants (Chinese Patent No. ZL96115937.5; ZL97107076.8) and existing sustained-release microspheres for the treatment of brain tumors (ZL00809160.9) or U.S. Patent (US5,651,986) all have inadequacies. Easy operation, poor curative effect, many complications, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] Put 80mg of polyphenylene propane (p-CPP: 20:80 of sebacic acid (SA)) copolymer into the container respectively, then add 100ml of dichloromethane, dissolve and mix well, then add 10mg of 5-FU and 10mg of goserelin were re-shaken and spray-dried to prepare microspheres for injection containing 10% 5-FU and 10% goserelin. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection with a viscosity of 360cp-480cp (at 25°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 10-15 days, and the drug release time in mice subcutaneous is about 20-30 days.

Embodiment 2

[0108] Put 80mg of polyphenylpropane (p-CPP: 50:50 of sebacic acid (SA)) copolymer into the container respectively, then add 100ml of dichloromethane, dissolve and mix well, then add 5mg of 5-FU and 15mg of goserelin were re-shaken and spray-dried to prepare microspheres for injection containing 5% 5-FU and 15% goserelin. Then suspend the microspheres in physiological saline containing 1.5% carboxymethylcellulose sodium to prepare the corresponding suspension-type sustained-release injection with a viscosity of 380cp-460cp (at 25°C-30°C). The drug release time of the sustained release injection in physiological saline in vitro is 14-20 days, and the drug release time in mice subcutaneous is about 25-35 days.

Embodiment 3

[0110] The method steps for processing into sustained-release injections are the same as in Example 2, but the difference is that the anti-cancer active ingredients and their weight percentages are: 15% 5-FU and 5% goserelin, suspension-type slow-release injections The viscosity of the release injection is 420cp-520cp (at 25°C-30°C). The release time of the slow-release injection in physiological saline in vitro is 15-22 days, and the release time in mice subcutaneous is about 25-35 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
glass transition temperatureaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

A slowly-release anticancer medicine in the form of injection or implant is disclosed. Said slowly-release injection is composed of a special solvent containing suspending aid and the slowly-release microballs consisting anticance medicine, iterstitial hydrolyte and slowly-releasing auxiliary. Said anticancer medicine is chosen from 5-FU, vincristine, etc. Said interstitial hydrolyte is chosen from collagenase, relaxin, etc. Said slowly-releasing auxiliary is chosen from polylactic acid, FAD, polyethanediol, etc.

Description

(1) Technical field [0001] The invention relates to an anticancer slow-release agent containing fluorouracil (5-FU) and its synergist and a preparation method thereof, belonging to the technical field of medicines. Sustained-release preparations are mainly sustained-release injections and sustained-release implants. (2) Background technology [0002] As a commonly used chemotherapeutic drug, 5-fluorouracil (5-FU) has been widely used in the treatment of various malignant tumors, and the effect is more obvious. However, its unexpected neurotoxicity greatly limits the application of this drug. Blood vessels, connective tissue, matrix proteins, fibrin, and collagen in the tumor stroma not only provide scaffolds and essential nutrients for the growth of tumor cells, but also affect the penetration of chemotherapy drugs around the tumor and in the tumor tissue and diffusion (see Netti et al. "The influence of the status of the extracellular matrix on the delivery of drugs in so...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/10A61K31/513A61K38/08A61K31/475A61K47/34A61P35/00A61K47/26
Inventor 孔庆忠刘恩祥
Owner SHANDONG LANJIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products